Is AOD-9604 FDA Approved? Regulatory Status Explained

AOD-9604 is sold on dozens of research peptide sites and supplement platforms, marketed with weight-loss promises that sound clinical. Here's what those sites won't tell you upfront: the peptide has zero FDA approval for human use. Not as a drug, not as a supplement, not for weight loss or any other therapeutic indication. It failed Phase 2b obesity trials in 2007 after $30 million in development costs, and in 2021, the Therapeutic Goods Administration (TGA) in Australia withdrew its complementary medicine registration following post-market safety review.

Our team has tracked the regulatory pathway of AOD-9604 since its initial development at Monash University. The gap between marketing claims and regulatory reality is significant. And understanding that gap matters if you're evaluating this peptide for research or considering products that contain it.

What is the current FDA approval status of AOD-9604?

AOD-9604 does not have FDA approval for any indication. It is not classified as a prescription medication, is not listed as a dietary supplement approved for human consumption, and does not appear in the FDA's Inactive Ingredient Database. The peptide is legally available only as a research-grade compound under Section 201(ff)(3) of the Federal Food, Drug, and Cosmetic Act. Which exempts substances 'intended for investigational use' from pre-market approval.

The AOD-9604 FDA approved status is legally nonexistent. The peptide was developed as a synthetic fragment of human growth hormone (HGH), specifically amino acids 176–191 of the C-terminal region, designed to replicate HGH's lipolytic effects without impacting glucose metabolism or IGF-1 production. Phase 1 safety trials in 2003–2004 showed acceptable tolerance at doses up to 1mg daily, but the Phase 2b multi-center trial (300+ participants, 12 weeks, randomised double-blind) published in 2007 showed no statistically significant fat mass reduction versus placebo. Mean weight loss in the treatment group was 2.6kg compared to 2.1kg in the placebo arm. A 0.5kg difference that failed to meet the study's primary endpoint.

Why AOD-9604 Never Gained FDA Approval

The failure of AOD-9604 in clinical trials wasn't due to safety red flags. It was efficacy. The Phase 2b obesity trial (ClinicalTrials.gov identifier NCT00315172) enrolled 304 obese adults (BMI 30–40) across multiple sites, randomising participants to receive either AOD-9604 1mg subcutaneously daily or placebo for 12 weeks alongside a hypocaloric diet. The primary endpoint was reduction in body fat percentage measured by DEXA scan. Secondary endpoints included waist circumference, lipid profiles, and fasting glucose.

Results showed no significant difference between groups. Body fat percentage decreased 1.1% in the treatment arm versus 0.9% in placebo. Waist circumference dropped 3.2cm in both groups. The study authors concluded that AOD-9604 'did not demonstrate efficacy superior to placebo in reducing body fat in obese adults.' The peptide's developer, Metabolic Pharmaceuticals, withdrew the compound from further clinical development in 2007 and pivoted to other pipeline candidates.

The FDA has not reviewed AOD-9604 for approval because no New Drug Application (NDA) or Investigational New Drug (IND) application has ever been submitted. Without IND approval, a compound cannot proceed past early-phase trials; without NDA submission, it cannot enter the approval review process. AOD-9604's development stopped at Phase 2b. The efficacy failure meant there was no pathway forward to Phase 3 or regulatory filing.

The TGA Withdrawal and What It Signals

In Australia, AOD-9604 was briefly listed on the Australian Register of Therapeutic Goods (ARTG) as a complementary medicine under the brand name Regenabolic, approved in 2010 for 'oral administration to assist in the reduction of body fat.' This listing did not require the same clinical trial evidence as prescription medications. Complementary medicines in Australia are regulated under a lower-evidence framework that permits market entry based on traditional use claims or preliminary data.

In January 2021, the TGA cancelled the registration of AOD-9604-containing products following a post-market review that identified 'concerns relating to the quality, safety, and efficacy' of the listed formulations. The TGA cited lack of robust evidence for the claimed weight-loss effects and raised questions about long-term safety data gaps. Products containing AOD-9604 were removed from the ARTG and can no longer be legally sold as therapeutic goods in Australia.

This regulatory action matters because the TGA operates under a framework comparable to the FDA. Both agencies evaluate drugs under similar safety and efficacy standards. The TGA's withdrawal after 11 years on the market signals that even under the lower-evidence complementary medicine pathway, AOD-9604 could not sustain regulatory approval when subjected to post-market scrutiny.

AOD-9604 FDA Approved Status: Research vs Supplement Markets

The AOD-9604 FDA approved status question matters most when evaluating product claims. If a website, clinic, or supplement brand markets AOD-9604 with language like 'clinically proven weight loss' or 'reduces body fat,' they are making therapeutic claims that classify the product as an unapproved drug under FDA regulations. The FDA has issued warning letters to companies selling peptides with therapeutic claims. Examples include Titan Medical Center (2019) and multiple online peptide retailers flagged for marketing unapproved drugs.

Our experience working with research institutions shows that high-purity AOD-9604 from certified suppliers like Real Peptides is legally available for laboratory research under cGMP manufacturing standards. That research-grade classification is the only defensible use case under current U.S. law. Clinical use. Whether through compounding pharmacies or direct-to-consumer telemedicine platforms. Operates in regulatory grey zones that carry legal and medical risk.

AOD-9604 FDA Approved Status Comparison

What If: AOD-9604 Scenarios

What If I'm Prescribed Compounded AOD-9604 by a Telemedicine Clinic?

Verify the prescribing physician is licensed in your state and confirm the compounding pharmacy is registered as a 503A or 503B facility. Compounded AOD-9604 is legal only with a valid prescription for off-label use. But off-label prescribing for weight loss without documented medical necessity (e.g., obesity with comorbid conditions) may not meet standard-of-care thresholds. Insurance will not cover compounded AOD-9604 because it lacks FDA approval, and you assume full financial and medical risk.

What If I Buy AOD-9604 as a Research Chemical Online?

If purchased from a cGMP-certified supplier like Real Peptides and labeled 'for research use only,' possession for personal laboratory research is legal under FFDCA Section 201(ff)(3). Self-administration for weight loss or athletic performance is not legal. It converts the product from a research chemical to an unapproved drug used for therapeutic purposes. The FDA does not actively prosecute individuals for personal peptide use, but clinics and suppliers marketing AOD-9604 for human consumption face enforcement risk.

What If I See AOD-9604 Listed as an Ingredient in an OTC Supplement?

That product is an unapproved drug under FDA regulations. Supplements cannot contain synthetic peptides that make therapeutic claims. Doing so reclassifies the product under FDCA drug definitions. The FDA has sent warning letters to multiple companies selling peptide-containing supplements with fat-loss or muscle-building claims. Purchase and consumption carry risk. Product purity, dosage accuracy, and contamination are unverified.

The Unfiltered Truth About AOD-9604's Regulatory Standing

Here's the honest answer: AOD-9604 is not a supplement that slipped through regulatory cracks. It's a failed drug candidate that was thoroughly tested, found ineffective, and withdrawn from development. The Phase 2b trial wasn't underpowered or poorly designed. It was a properly controlled, multi-site, double-blind study with over 300 participants. The peptide simply didn't work better than placebo.

The TGA withdrawal in Australia should be a red flag. Regulatory agencies don't cancel product registrations lightly. The decision came after 11 years on the market and reflected post-market data showing the initial approval was not justified by the evidence. If a peptide can't maintain approval even under Australia's lower-evidence complementary medicine framework, that tells you something meaningful about the efficacy and safety profile.

Marketing AOD-9604 as a 'research peptide' is technically accurate. But only if 'research' means in vitro or animal studies, not human self-experimentation. The regulatory pathway for peptides is clear: Phase 1 safety, Phase 2 efficacy, Phase 3 confirmation, NDA submission, FDA review. AOD-9604 stopped at Phase 2 because it failed the efficacy test. Everything sold after that point is either legitimate laboratory research supply or regulatory arbitrage.

The current state of the AOD-9604 FDA approved status is final. Unless a new sponsor funds a redesigned Phase 2 trial with a different endpoint and succeeds where Metabolic Pharmaceuticals failed, this peptide will remain outside the regulatory approval pathway. Researchers evaluating AOD-9604 should focus on what the clinical evidence actually shows. Not what marketing copy implies. And purchase only from verified cGMP sources that make no therapeutic claims.

If you're considering AOD-9604 for research purposes, make sure you're working with suppliers who understand the regulatory distinction. At Real Peptides, every peptide is synthesized with exact amino-acid sequencing and third-party purity verification, ensuring research-grade consistency without therapeutic claims. That's the standard the field requires. Precision, transparency, and regulatory compliance at every step.